Vanderbilt HIV Clinical Trials Unit

描述（由申请人提供）：艾滋病毒大流行是对健康和发展的最大持续威胁之一，30多年来一直没有得到承认。NIAID资助的临床试验网络在协调应对艾滋病毒/艾滋病领域的关键研究问题方面发挥了关键作用。拟议的范德比尔特临床试验单位（CTU）是范德比尔特大学和华盛顿大学之间的合作伙伴关系，包括三个表现最好的现任临床研究中心（CRS），跨越艾滋病临床试验组（ACTG）的治疗使命和艾滋病疫苗试验网络（HVTN）的疫苗使命。这建立在范德比尔特治疗学CRS和范德比尔特疫苗CRS之间已经建立的伙伴关系的基础上，并增加了与华盛顿大学治疗学CRS的新伙伴关系。后两个网站自1987-1988年成立以来一直是HVTN和ACTG的成员。该CTU的领导人在人类基因组学和艾滋病毒疾病的神经学方面等领域为网络做出了具有高度影响力的独特科学和方案贡献。展望未来，该CTU将继续利用范德比尔特在生物医学信息学方面的机构优势，实施灵活、实时、可共享的信息学工具， 优化CTU的表现该CTU还受益于与其他主要NIH计划的密切联系，包括范德比尔特作为全国约60个临床和转化科学奖（CTSA）网络的协调中心，NIAID赞助的国际流行病学数据库评估艾滋病（leDEA）的七个全球地区，以及leDEA拉丁美洲地区的七个国家。在拟议的发现期间，范德比尔特CTU将为ACTG的重点关注艾滋病毒/艾滋病、结核病和病毒性肝炎的科学优先事项做出实质性贡献，并将为HVTN的主要科学优先事项做出实质性贡献，即开发和测试安全有效的艾滋病毒疫苗。 相关性：公共卫生将受益于范德比尔特临床试验单位的努力，以支持制定高效的预防和治疗艾滋病毒感染，结核病和病毒性肝炎的战略。

DESCRIPTION (provided by applicant): The HIV pandemic is one of the greatest ongoing threats to health and development, over 30 years past its recognition. The NIAID-funded Clinical Trials Networks have played critical roles in the coordinated response to key research questions in the HIV/AIDS field. The proposed Vanderbilt Clinical Trials Unit (CTU) is a partnership between Vanderbilt University and Washington University, comprising three top-performing incumbent Clinical Research Sites (CRSs) that span the therapeutics mission of the AIDS Clinical Trials Group (ACTG) and the vaccine mission of the HIV Vaccine Trials Network (HVTN). This builds upon the already established partnership between the Vanderbilt Therapeutics CRS and the Vanderbilt Vaccine CRS, and adds a new partnership with the Washington University Therapeutics CRS. The latter two sites have been members of the HVTN and ACTG since the inception of these Networks in 1987-1988. The leaders of this CTU have made high-impact, unique scientific and programmatic contributions to the Networks in areas that include human genomics and neurological aspects of HIV disease. Moving forward this CTU will continue its track record of programmatic impact by leveraging Vanderbilt's institutional strength in biomedical informatics to implement flexible, real-time, shareable informatics tools to optimize CTU performance. This CTU also benefits from close ties to other major NIH programs including Vanderbilt's roles as Coordinating Center for the nationwide network of approximately 60 Clinical and Translational Science Awards (CTSA), for the seven worldwide regions of the NIAID-sponsored International Epidemiologic Databases to Evaluate AIDS (leDEA), and for the seven countries of leDEA's Latin American region. During the proposed finding period the Vanderbilt CTU will make substantial contributions to the ACTG's scientific priorities focused on HIV/AIDS, tuberculosis, and viral hepatitis, and will make substantial contributions to the HVTN's major scientific priority of developing and testing a safe and effective vaccine for HIV. RELEVANCE: Public health will benefit from Vanderbilt Clinical Trials Unit's efforts in support of developing highly effective prevention and treatment strategies for HIV infection, tuberculosis, and viral hepatitis.